Literature DB >> 17665292

Actuality of Warburg's views in our understanding of renal cancer metabolism.

Catherine Godinot1, Elodie de Laplanche, Eric Hervouet, Hélène Simonnet.   

Abstract

More than 50 years ago, Warburg proposed that the shift in glucose metabolism from oxidative phosphorylation (OXPHOS) to glycolysis occurring in spite of an adequate oxygen supply was at the root of cancer. This hypothesis often disregarded over the following years has recently stirred up much interest due to progress made in cancer genetics and proteomics. Studies related to renal cancers have been particularly informative to understand how abnormal use of glucose and decrease in OXPHOS are linked to cell proliferation in tumors. Indeed, in aggressive tumors such as clear cell renal carcinoma, the von Hippel-Lindau factor invalidation stabilizes the hypoxia-inducible factor (HIF) in the presence of oxygen. HIF stimulating glycolytic gene expression increases the glycolytic flux. Deficiencies in genes involved in oxidative phosphorylation that can explain the down-regulation of OXPHOS components also begin to be identified. These findings are important in the search for novel therapeutic approaches to cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17665292     DOI: 10.1007/s10863-007-9088-8

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  68 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Glucose-6-phosphatase mRNA levels in kidney isolated tubule suspensions are increased by dexamethasone and decreased by insulin.

Authors:  H Simonnet
Journal:  Metabolism       Date:  1999-08       Impact factor: 8.694

Review 3.  [Classification of primary kidney tumors in adults].

Authors:  V Molinié; B Cochand-Priollet; F Staroz; A Vieillefond
Journal:  Ann Pathol       Date:  1998-02       Impact factor: 0.407

4.  Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma.

Authors:  Rachel A Craven; Sarah Hanrahan; Nick Totty; Patricia Harnden; Anthea J Stanley; Eamonn R Maher; Adrian L Harris; William S Trimble; Peter J Selby; Rosamonde E Banks
Journal:  Proteomics       Date:  2006-07       Impact factor: 3.984

5.  Tissue-specific cytochrome c oxidase assembly defects due to mutations in SCO2 and SURF1.

Authors:  Lukas Stiburek; Katerina Vesela; Hana Hansikova; Petr Pecina; Marketa Tesarova; Leona Cerna; Josef Houstek; Jiri Zeman
Journal:  Biochem J       Date:  2005-12-15       Impact factor: 3.857

6.  Inhibition of cytochrome c oxidase subunit 4 precursor processing by the hypoxia mimic cobalt chloride.

Authors:  Eric Hervouet; Petr Pecina; Jocelyne Demont; Alena Vojtísková; Hélène Simonnet; Josef Houstek; Catherine Godinot
Journal:  Biochem Biophys Res Commun       Date:  2006-04-19       Impact factor: 3.575

Review 7.  Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression.

Authors:  Thomas Kietzmann; Agnes Görlach
Journal:  Semin Cell Dev Biol       Date:  2005 Aug-Oct       Impact factor: 7.727

Review 8.  Novel treatments for metastatic renal cell carcinoma.

Authors:  D J van Spronsen; P F A Mulders; P H M De Mulder
Journal:  Crit Rev Oncol Hematol       Date:  2005-09       Impact factor: 6.312

9.  PGC-1-related coactivator and targets are upregulated in thyroid oncocytoma.

Authors:  Frédérique Savagner; Delphine Mirebeau; Caroline Jacques; Serge Guyetant; Catherine Morgan; Brigitte Franc; Pascal Reynier; Yves Malthièry
Journal:  Biochem Biophys Res Commun       Date:  2003-10-24       Impact factor: 3.575

10.  Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention.

Authors:  Peter L Pedersen; Saroj Mathupala; Annette Rempel; J F Geschwind; Young Hee Ko
Journal:  Biochim Biophys Acta       Date:  2002-09-10
View more
  15 in total

Review 1.  How far is the horizon? From current targets to future drugs in advanced renal cancer.

Authors:  Stephan Kruck; Axel S Merseburger; Arnulf Stenzl; Jens Bedke
Journal:  World J Urol       Date:  2013-05-09       Impact factor: 4.226

2.  Molecular analysis of tumor margins by MALDI mass spectrometry in renal carcinoma.

Authors:  Stacey R Oppenheimer; Deming Mi; Melinda E Sanders; Richard M Caprioli
Journal:  J Proteome Res       Date:  2010-05-07       Impact factor: 4.466

Review 3.  Lipids, mitochondria and cell death: implications in neuro-oncology.

Authors:  Alison Colquhoun
Journal:  Mol Neurobiol       Date:  2010-04-29       Impact factor: 5.590

4.  Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications.

Authors:  Jehonathan H Pinthus; Kaitlyn F Whelan; Daniel Gallino; Jian-Ping Lu; Nathan Rothschild
Journal:  Can Urol Assoc J       Date:  2011-08       Impact factor: 1.862

5.  Variable toxicological response to the loss of OXPHOS through 1-methyl-4-phenylpyridinium-induced mitochondrial damage and anoxia in diverse neural immortal cell lines.

Authors:  Elizabeth A Mazzio; Youssef I Soliman; Karam F A Soliman
Journal:  Cell Biol Toxicol       Date:  2010-04-18       Impact factor: 6.691

6.  Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine.

Authors:  Na Li; Huanni Li; Ya Wang; Lanqin Cao; Xianquan Zhan
Journal:  EPMA J       Date:  2020-10-10       Impact factor: 6.543

Review 7.  Renal Cell Carcinoma: Molecular Aspects.

Authors:  Aman Kumar; Niti Kumari; Vinny Gupta; Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2017-11-13

8.  Analysis of differentially expressed mitochondrial proteins in chromophobe renal cell carcinomas and renal oncocytomas by 2-D gel electrophoresis.

Authors:  Maria V Yusenko; Thomas Ruppert; Gyula Kovacs
Journal:  Int J Biol Sci       Date:  2010-04-23       Impact factor: 6.580

9.  Cancer as a metabolic disease.

Authors:  Thomas N Seyfried; Laura M Shelton
Journal:  Nutr Metab (Lond)       Date:  2010-01-27       Impact factor: 4.169

10.  Mitochondrial and nuclear genes of mitochondrial components in cancer.

Authors:  E Kirches
Journal:  Curr Genomics       Date:  2009-06       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.